CDSCO vs FDA vs EU MDR for Biocompatibility Files

The Reusable Core Is Smaller Than Teams Think

A genuinely reusable core package can be valuable. That usually includes the current device description, patient-contacting materials, contact duration, manufacturing and sterilization context, available chemistry data, testing reports, and the risk-management bridge behind the biological evaluation.

But that core still needs three different presentation layers. If you reuse the evidence and forget to rebuild the submission logic around the target market, the file starts to look copied instead of considered.

CDSCO: The India Pathway and Dossier Context Matter First

For India submissions, the practical question is often not "What does CDSCO want instead of ISO 10993?" It is "How should the biological evaluation material be organized and justified for the actual MDR 2017 route being used?"

Under India's Medical Devices Rules, 2017, the dossier framework for higher-risk devices includes material details and, where testing is undertaken, evidence on physical, chemical, biological, microbiological, and toxicological characteristics of the device. That means the biocompatibility story usually sits inside a broader submission architecture rather than standing alone as a separate FDA-style summary.

• What usually matters most: the real India pathway, applicant structure, applicable standards, and whether the dossier is directionally usable for the route in view.
• What often goes wrong: a team drops an FDA or EU-style summary into the file without checking whether the India dossier framing, materials description, and test evidence are aligned to the actual submission plan.
• What can travel: core endpoint logic, test reports, chemistry evidence, and risk reasoning, if they are still device-current and not route-dependent in wording.

In practice, CDSCO work often feels less like "write one polished biocompatibility memo" and more like "make sure the biological evidence makes sense inside the India-specific dossier and pathway context."

FDA: Finished-Device Logic Is Usually the Deciding Standard

FDA may rely on ISO 10993-1, but it applies that framework in a very explicit, submission-facing way. FDA's biocompatibility resources emphasise that the device is assessed in its final finished form, including sterilization where relevant, and that risk assessment must consider not just materials, but also processing, manufacturing methods, and residuals.

• What reviewers expect: a clear explanation of tissue contact, duration, endpoint selection, omitted endpoints, chemistry rationale, and how all of that applies to the marketed device configuration.
• What often goes wrong: teams present material-level comfort statements without a device-level risk story, or they rely on old test reports without explaining what current manufacturing or sterilization does to the final risk position.
• What FDA is less forgiving about: unsupported waiver logic, vague extractables arguments, and summaries that read like standards notes instead of reviewer-ready justification.

That is why a file can feel scientifically respectable and still attract FDA questions quickly. The problem is often not missing data alone. It is weak finished-device reasoning.

EU MDR: Stronger Cross-Referencing and GSPR Mapping

EU MDR raises the bar differently. Annex I, Chapter II, Section 10 focuses on chemical, physical, and biological properties, including materials, compatibility with tissues and body fluids, contaminants and residues, and substances or particles released from the device. Annex II then expects the technical documentation to show how conformity with applicable general safety and performance requirements is actually demonstrated and where the evidence lives.

• What reviewers expect: the biological evaluation should be coherent with risk management, design information, chemistry, PMS thinking where relevant, and the broader technical documentation.
• What often goes wrong: the file contains decent evidence, but the links back to the applicable GSPRs are implied rather than explicit.
• What EU MDR exposes quickly: legacy documentation that still reads like a self-contained report instead of one evidence layer inside a controlled technical file.

So while FDA often punishes weak finished-device logic, EU MDR often punishes weak document architecture and traceability.

Where One Cross-Market File Usually Breaks

Most multi-market failures come from reuse at the wrong layer. Teams reuse the visible narrative instead of reusing the underlying evidence.

• Copied endpoint tables: the table travels, but the explanation for why those endpoints are sufficient is market-specific.
• Waiver rationale that is technically true but badly framed: acceptable science can still be communicated in the wrong regulatory language.
• Chemistry without placement: extractables, residuals, or TRA outputs exist, but the file does not show where they support the biological conclusion.
• Route ambiguity: the team has not fully resolved whether the file is serving India planning, FDA premarket review, EU MDR technical documentation, or all three at once.
• Version drift: test reports and materials history reflect an older device state than the one now being submitted.

A More Workable Multi-Market Strategy

The better approach is to build one defensible evidence core and three market-facing wrappers around it.

• Core evidence layer: device definition, patient-contacting materials, manufacturing and sterilization context, chemistry, testing, literature, and risk-management bridge.
• India layer: confirm the actual MDR 2017 route, applicant context, dossier structure, and where biological evidence needs to sit within that pathway.
• FDA layer: build a concise finished-device argument that explains why the current marketed configuration is adequately assessed.
• EU MDR layer: map the same evidence back to Annex I requirements and technical-documentation cross-references.

If that feels like "extra writing," it is. But it is usually cheaper than forcing one generic narrative to carry three different review styles.